Table 1.

Demographic and baseline clinical characteristics of study participants

Subject ID	Group	Ethnicity	Gender	Birth Mode	Gestational Term	a Antibiotics intake prior to diagnosis	b Risk Group	Chemotherapy duration (months)	Follow-up Duration (months)
AL3	Patient	Malay	Female	Vaginal	Term	Yes	Intermediate	27	34
AL4	Patient	Malay	Male	NA	Term	Yes	Standard	25	34
AL8	Patient	Malay	Male	Vaginal	Term	Yes	Standard	25	29
AL10	Patient	Malay	Male	Vaginal	Term	Yes	Intermediate	27	31
AL13	Patient	Malay	Male	Vaginal	Term	Yes	Standard	25	30
AL15	Patient	Malay	Male	Vaginal	Term	Yes	Intermediate	26	31
AL18	Patient	Malay	Male	Vaginal	Post-term	Yes	Standard	24	29
						a Antibiotics intake prior to sampling
IM18C	Control	Malay	Male	Vaginal	Term	No	–	–	–
ConC1	Control	Malay	Male	Vaginal	Term	No	–	–	–
ConC2	Control	Malay	Male	Vaginal	Term	No	–	–	–
ConC4	Control	Malay	Female	Vaginal	Term	No	–	–	–
ConC5	Control	Malay	Male	Vaginal	Term	No	–	–	–
ConCP3	Control	Malay	Male	Vaginal	Term	No	–	–	–
ConCP5	Control	Malay	Male	Vaginal	Term	No	–	–	–

NA no information available

^aAntibiotic intake within 1 month prior to baseline sample collection

^bRisk group = ALL patients were assigned to one of the 3 risk groups (ie: standard, intermediate, high), depending on their response to the chemotherapy and special laboratory tests, according to Ma-Spore ALL 2010 treatment protocol